{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:15:59Z","timestamp":1786119359931,"version":"build-2736575974"},"reference-count":23,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"17","license":[{"start":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T00:00:00Z","timestamp":1776988800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Jiangsu Provincial Hospital of Traditional Chinese Medicine Institutional Research Project"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,4,24]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Qi-exchange moxibustion (QEM) at the conception vessel 8 (Shenque acupoint) is reported to ameliorate symptoms in ulcerative colitis (UC), yet prospective evidence for its added value to mesalazine (and the biomarkers that may predict response) remain undefined. We explored clinical efficacy and baseline inflammatory biomarkers associated with QEM treatment in mild-to-moderate UC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>In this investigator-initiated, prospective 2-arm cohort conducted at a single tertiary center (July 2020 to March 2024), 123 adults with mild-to-moderate UC on stable mesalazine (2.0\u20133.0\u2009g\/day) were enrolled: 68 received adjuvant QEM 3 times weekly for 8 weeks and 55 continued mesalazine alone. The primary endpoint was clinical response (\u2265\u20052-point reduction in modified Mayo score plus\u2005\u2265\u200520 point increase in inflammatory bowel disease questionnaire) at week 8. Secondary outcomes included remission (modified Mayo\u2005\u2264\u20051), mucosal healing (endoscopic Mayo\u2005=\u20050), and changes in inflammatory bowel disease questionnaire. Baseline fecal calprotectin and serum interleukin-6\/tumor necrosis factor-alpha were measured in the QEM arm to identify response predictors using multivariable logistic regression.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Week-8 clinical response was achieved in 46\/68 (67.6%) patients with QEM versus 21\/55 (38.2%) controls (odds ratios (OR) 3.38, 95% confidence intervals (CI) 1.68\u20136.81;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005=\u2005.001). Remission (42.6% vs 20.0%;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005=\u2005.007) and mucosal healing (38.2% vs 16.4%;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005=\u2005.006) were also higher with QEM. In the QEM cohort, responders displayed elevated baseline calprotectin (192 vs 95 \u00b5g\/g;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005=\u2005.008), IL-6 (17.8 vs 10.4 pg\/mL;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005=\u2005.012) and tumor necrosis factor-alpha (14.9 vs 8.7 pg\/mL;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005=\u2005.018). Each 1-standard deviation increase in log-calprotectin independently predicted response (adjusted OR 1.45, 95% CI 1.09\u20131.93;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005=\u2005.011); association was stronger in moderate disease (OR 1.73, 95% CI 1.24\u20132.42) and in the high-calprotectin subgroup (OR 1.69, 95% CI 1.22\u20132.35).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Adjuvant QEM significantly enhanced clinical and endoscopic outcomes in mesalazine-treated mild-to-moderate UC. Baseline calprotectin emerged as a robust, syndrome-specific predictor of QEM responsiveness, supporting a precision-medicine approach to thermal-acupoint therapy in UC.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/md.0000000000048501","type":"journal-article","created":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T07:02:33Z","timestamp":1777273353000},"page":"e48501","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Biomarkers predicting response to qi-exchange moxibustion in ulcerative colitis: A prospective 2-arm cohort study"],"prefix":"10.1097","volume":"105","author":[{"given":"Min","family":"Li","sequence":"first","affiliation":[{"name":"Gastroenterology Department, Jiangsu Province Traditional Chinese Medicine Hospital, Nanjing, Jiangsu, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingwei","family":"Kong","sequence":"additional","affiliation":[{"name":"Gastroenterology Department, Jiangsu Province Traditional Chinese Medicine Hospital, Nanjing, Jiangsu, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaqin","family":"Li","sequence":"additional","affiliation":[{"name":"Gastroenterology Department, Jiangsu Province Traditional Chinese Medicine Hospital, Nanjing, Jiangsu, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruo","family":"Wang","sequence":"additional","affiliation":[{"name":"Gastroenterology Department, Jiangsu Province Traditional Chinese Medicine Hospital, Nanjing, Jiangsu, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng","family":"Peng","sequence":"additional","affiliation":[{"name":"Gastroenterology Department, Jiangsu Province Traditional Chinese Medicine Hospital, Nanjing, Jiangsu, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingjing","family":"Wang","sequence":"additional","affiliation":[{"name":"Gastroenterology Department, Jiangsu Province Traditional Chinese Medicine Hospital, Nanjing, Jiangsu, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-1824-5050","authenticated-orcid":false,"given":"Pinju","family":"Lv","sequence":"additional","affiliation":[{"name":"Gastroenterology Department, Jiangsu Province Traditional Chinese Medicine Hospital, Nanjing, Jiangsu, China."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20260622","doi-asserted-by":"crossref","first-page":"2769","DOI":"10.1016\/S0140-6736(17)32448-0","article-title":"Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies.","volume":"390","author":"Ng","year":"2017","journal-title":"Lancet"},{"key":"R2-20260622","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/s41572-020-0205-x","article-title":"Ulcerative colitis.","volume":"6","author":"Kobayashi","year":"2020","journal-title":"Nat Rev Dis Primers"},{"key":"R3-20260622","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1038\/nrgastro.2015.34","article-title":"Epidemiology and risk factors for IBD.","volume":"12","author":"Ananthakrishnan","year":"2015","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"R4-20260622","first-page":"CD000544","article-title":"Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis.","volume":"2","author":"Sutherland","year":"2006","journal-title":"Cochrane Database Syst Rev"},{"key":"R5-20260622","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1080\/00365520802600961","article-title":"Clinical course during the first 10 years of ulcerative colitis: results from a population-based inception cohort (IBSEN Study).","volume":"44","author":"Solberg","year":"2009","journal-title":"Scand J Gastroenterol"},{"key":"R6-20260622","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/1471-230X-10-36","article-title":"Moxibustion for ulcerative colitis: a systematic review and meta-analysis.","volume":"10","author":"Lee","year":"2010","journal-title":"BMC Gastroenterol"},{"key":"R7-20260622","doi-asserted-by":"crossref","first-page":"e078878","DOI":"10.1136\/bmjopen-2023-078878","article-title":"Efficacy and safety of moxibustion for ulcerative colitis: protocol for a systematic review and meta-analysis.","volume":"14","author":"Li","year":"2024","journal-title":"BMJ Open"},{"key":"R8-20260622","first-page":"120","article-title":"Herbal-cake-partitioned moxibustion of \u201cShenque\u201d (CV8) has a relative specific effect in relieving abdominal pain and in regulating neuroendocrine-immune network in primary dysmenorrhea rats.","volume":"44","author":"Chen","year":"2019","journal-title":"Zhen Ci Yan Jiu"},{"key":"R9-20260622","doi-asserted-by":"crossref","first-page":"2218","DOI":"10.1002\/ibd.22917","article-title":"Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease.","volume":"18","author":"D\u2019Haens","year":"2012","journal-title":"Inflamm Bowel Dis"},{"key":"R10-20260622","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1136\/gutjnl-2012-304258","article-title":"Once-daily budesonide MMX in active, mild-to-moderate ulcerative colitis: results from the randomised CORE II study.","volume":"63","author":"Travis","year":"2014","journal-title":"Gut"},{"key":"R11-20260622","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1215734","article-title":"Vedolizumab as induction and maintenance therapy for ulcerative colitis.","volume":"369","author":"Feagan","year":"2013","journal-title":"N Engl J Med"},{"key":"R12-20260622","doi-asserted-by":"crossref","first-page":"17562848231188549","DOI":"10.1177\/17562848231188549","article-title":"Efficacy and safety of oral beclomethasone dipropionate and budesonide MMX versus 5-aminosalicylates or placebo in ulcerative colitis: a systematic review and meta-analysis.","volume":"16","author":"Barberio","year":"2023","journal-title":"Ther Adv Gastroenterol"},{"key":"R13-20260622","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.trsl.2015.09.002","article-title":"Pathway-based approaches to the treatment of inflammatory bowel disease.","volume":"167","author":"Bamias","year":"2016","journal-title":"Transl Res"},{"key":"R14-20260622","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1186\/s43162-025-00461-6","article-title":"Immunotherapy for ulcerative colitis: targeting innate and adaptive immune responses for better clinical outcomes.","volume":"37","author":"Shah","year":"2025","journal-title":"Egypt J Intern Med"},{"key":"R15-20260622","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1038\/nature02732","article-title":"The principle of temperature-dependent gating in cold- and heat-sensitive TRP channels.","volume":"430","author":"Voets","year":"2004","journal-title":"Nature"},{"key":"R16-20260622","doi-asserted-by":"crossref","first-page":"S139","DOI":"10.33549\/physiolres.933671","article-title":"Vagal-immune interactions involved in cholinergic anti-inflammatory pathway.","volume":"66","author":"Zila","year":"2017","journal-title":"Physiol Res"},{"key":"R17-20260622","doi-asserted-by":"crossref","first-page":"117364","DOI":"10.1016\/j.jep.2023.117364","article-title":"The water-soluble subfraction from Artemisia argyi alleviates LPS-induced inflammatory responses via multiple pathways and targets in vitro and in vivo.","volume":"319","author":"Chen","year":"2024","journal-title":"J Ethnopharmacol"},{"key":"R18-20260622","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1111\/jcmm.12934","article-title":"Cell surface-anchored syndecan-1 ameliorates intestinal inflammation and neutrophil transmigration in ulcerative colitis.","volume":"21","author":"Zhang","year":"2017","journal-title":"J Cell Mol Med"},{"key":"R19-20260622","doi-asserted-by":"crossref","first-page":"2747","DOI":"10.1007\/s12013-024-01391-w","article-title":"Hinesol attenuates DSS-induced ulcerative colitis through the suppression of Src-mediated NF-\u03baB and chemokine signaling pathway.","volume":"82","author":"Li","year":"2024","journal-title":"Cell Biochem Biophys"},{"key":"R20-20260622","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1007\/s10928-019-09652-5","article-title":"Tumor necrosis factor-mediated disposition of infliximab in ulcerative colitis patients.","volume":"46","author":"Berends","year":"2019","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"R21-20260622","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1038\/ajg.2014.146","article-title":"Development of an algorithm incorporating pharmacokinetics of adalimumab in inflammatory bowel diseases.","volume":"109","author":"Roblin","year":"2014","journal-title":"Am J Gastroenterol"},{"key":"R22-20260622","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1136\/gut.2009.178665","article-title":"Mucosal gene signatures to predict response to infliximab in patients with ulcerative colitis.","volume":"58","author":"Arijs","year":"2009","journal-title":"Gut"},{"key":"R23-20260622","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1038\/s41586-019-1237-9","article-title":"Multi-omics of the gut microbial ecosystem in inflammatory bowel diseases.","volume":"569","author":"Lloyd-Price","year":"2019","journal-title":"Nature"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000048501","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T18:08:12Z","timestamp":1786039692000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000048501"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,24]]},"references-count":23,"journal-issue":{"issue":"17","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000048501","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,24]]},"assertion":[{"value":"2025-11-22","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-04-08","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}